Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than corporate financial performance.
| Transaction Type | Price | Date |
|---|---|---|
| Ordinary Shares | £13.05 per share | October 7, 2010 |
| Ordinary Share ADRs | $41.42 per ADR | October 7, 2010 |
Material Changes
The filing details an increase in share interests for several executives and directors following the re-investment of dividends paid on October 7, 2010. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports personal share purchases by directors and executives, not corporate financial results.
- Transactions occurred on October 7, 2010, driven by dividend re-investment.
- Specific individuals notified include Dr M M Slaoui, Mr J M Clarke, Mr J R Stéphenne, and others.
- The Company Secretary, S M Bicknell, advised the company of this information on October 13, 2010.